安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Gilead Sciences
Gilead Sciences, a biopharma company, achieves bold ambitions to help make the world a healthier place, leading in HIV, liver disease, cancer inflammation
- Gilead Sciences: Company
Learn about the biopharmaceutical company Gilead Sciences, including mission, vision, values, history, impact, leadership, therapeutic areas and other information
- Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial . . .
“Gilead delivered another exceptionally strong full year and fourth quarter, with growth in our base business product sales of 8% for 2024 and 13% year-over-year for the fourth quarter,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer
- Medicines - Gilead Sciences
Access the list of approved Gilead therapies across virology including HIV, liver disease including hepatitis and primary biliary cholangitis, oncology inflammation
- U. S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly . . .
Gilead researchers have developed 12 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly
- Gilead U. S. Investment to Create $43 Billion in Value to U. S. Economy
This comprehensive investment further bolsters Gilead’s domestic research, development, and manufacturing capabilities while advancing the company’s mission to discover and develop life-changing medicines
- Virology, Inflammation, Oncology Pipeline | Gilead
Through science and innovative partnerships, Gilead expands research and development programs in virology, oncology, inflammation Learn about our pipeline
- First Clinical Data for Gilead’s Investigational Once-Yearly . . .
Gilead researchers have developed 12 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly
|
|
|